OEM/ODM Manufacturer Glioblastoma Multiforme - Capecitabine CAS 154361-50-9 Purity 98.0%~102.0% API High Quality – Ruifu

Manufacturer with High Purity and Stable Quality Commercial Supply Capecitabine (CAS: 154361-50-9) Related Intermediates: Capecitabine CAS: 154361-50-9 1,2,3-Triacetyl-5-deoxy-D-ribose CAS: 62211-93-2 2',3'-Di-O-acetyl-5'-deoxy-5-fluorocytidine CAS: 161599-46-8

Chemical Name	Capecitabine
CAS Number	154361-50-9
CAT Number	RF-API08
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C15H22FN3O6
Molecular Weight	359.35
Brand	Ruifu Chemical

Item	Specifications
Appearance	White Powder
Identification	IR Spectrum  Conform to the Standard
Identification	HPLC Conform to the Standard
Purity	98.0%~102.0%
Impurity A	≤0.30%
Impurity B	≤0.30%
Impurity C	≤0.30%
Single Unspecified Impurity	≤0.10%
Total Unspecified Impurities	≤0.50%
Total Impurities	≤1.5%
Moisture (K.F)	≤0.30%
Heavy Metals	≤10ppm
Residue on ignition	≤0.10%
Test Standard	Enterprise Standard
Usage	Capecitabine CAS: 154361-50-9 is widely used in metastatic breast cancer

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation. Manufacturer with High Purity and Stable Quality Commercial Supply Capecitabine (CAS: 154361-50-9) Related Intermediates: Capecitabine CAS: 154361-50-9 1,2,3-Triacetyl-5-deoxy-D-ribose CAS: 62211-93-2 2',3'-Di-O-acetyl-5'-deoxy-5-fluorocytidine CAS: 161599-46-8 Capecitabine is a new form of oral fluorinated pyrimidine drug. Capecitabine was developed by Roche Pharmaceuticals, and its commercial name is Xeloda. Capecitabine can change in vivo into 5- FU, an anti-metabolizim fluorine pyrimidine deoxynucleoside carbamate drug that targets cancer cells to inhibit cell division and disrupt RNA and protein synthesis. Its effects are significantly tied to the level of TP enzyme expression in neoplastic tissue and to DPD enzyme in vivo expression. It is suitable as further treatment for advanced primary or metastatic breast cancer patients who have not responded to paclitaxel or anthracycline antibiotics. As an anticancer drug, it is mostly used to treat advanced primary or metastatic breast cancer, as well as in treatment for non-small cell lung cancer, pancreatic cancer, bladder cancer, rectal cancer, colon cancer, gastric cancer, and other solid tumors. Many drugs such as taxanes (paclitaxel, docetaxel, mitomycin, cisplatin, etc.) can increase TP enzyme expression in neoplastic tissues and also have curative effects on gastric cancer. When used in combination with Capecitabine, these drugs can also improve Capecitabine’s anticancer abilities and produce synergistic effects.